LifeStance Health Group, Inc. (NASDAQ:LFST) Forecasted to Post Q2 2022 Earnings of ($0.02) Per Share

LifeStance Health Group, Inc. (NASDAQ:LFST – Get Rating) – Analysts at Jefferies Financial Group boosted their Q2 2022 EPS estimates for shares of LifeStance Health Group in a research report issued on Tuesday, May 10th. Jefferies Financial Group analyst S. Wissink now expects that the company will post earnings of ($0.02) per share for the quarter, up from their prior forecast of ($0.03). Jefferies Financial Group also issued estimates for LifeStance Health Group’s Q3 2022 earnings at ($0.01) EPS, FY2022 earnings at ($0.22) EPS, Q1 2023 earnings at $0.01 EPS, Q3 2023 earnings at $0.02 EPS, FY2023 earnings at $0.06 EPS and FY2024 earnings at $0.17 EPS.

LifeStance Health Group (NASDAQ:LFST – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). LifeStance Health Group had a negative net margin of 49.60% and a negative return on equity of 22.40%. The business had revenue of $203.10 million for the quarter, compared to analysts’ expectations of $191.47 million. The business’s revenue was up 41.9% on a year-over-year basis.

Several other analysts also recently weighed in on the company. The Goldman Sachs Group cut their price target on LifeStance Health Group from $15.00 to $10.00 and set a “neutral” rating on the stock in a research note on Monday, March 21st. UBS Group downgraded LifeStance Health Group from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $19.00 to $10.00 in a report on Thursday, March 17th. Finally, Zacks Investment Research upgraded LifeStance Health Group from a “sell” rating to a “hold” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.00.

LFST stock opened at $6.79 on Thursday. LifeStance Health Group has a fifty-two week low of $5.43 and a fifty-two week high of $29.81. The business’s 50 day moving average price is $9.00 and its two-hundred day moving average price is $9.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.28 and a current ratio of 2.28. The company has a market capitalization of $2.54 billion and a price-to-earnings ratio of -6.35.

In other news, CFO Jesse Michael Bruff sold 18,401 shares of the business’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $7.92, for a total transaction of $145,735.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Kevin Michael Mullins sold 46,283 shares of the company’s stock in a transaction on Wednesday, April 20th. The shares were sold at an average price of $10.68, for a total value of $494,302.44. Following the completion of the transaction, the insider now directly owns 5,669,472 shares in the company, valued at approximately $60,549,960.96. The disclosure for this sale can be found here.

Several hedge funds and other institutional investors have recently modified their holdings of LFST. Bank of America Corp DE acquired a new position in shares of LifeStance Health Group in the second quarter valued at about $200,000. SG Americas Securities LLC purchased a new position in shares of LifeStance Health Group in the third quarter valued at approximately $173,000. New York State Common Retirement Fund purchased a new position in shares of LifeStance Health Group in the third quarter valued at approximately $470,000. Deutsche Bank AG purchased a new position in LifeStance Health Group during the third quarter worth approximately $403,000. Finally, Principal Financial Group Inc. increased its stake in LifeStance Health Group by 1.8% during the third quarter. Principal Financial Group Inc. now owns 2,249,761 shares of the company’s stock worth $32,622,000 after acquiring an additional 39,594 shares during the last quarter. Hedge funds and other institutional investors own 80.71% of the company’s stock.

About LifeStance Health Group (Get Rating)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

Featured Stories